Tag Archives: apixaban market

Apixaban market Insights- Application Analysis, Regional Outlook(USA, Russia, Europe, Asia, Australia), Competitive Landscape And Forecasts, 2018-2023

The recent report, Apixaban market fundamentally discovers insights that enable stakeholders, business owners and field marketing executives to make effective investment decisions driven by facts – rather than guesswork.

The study aims at listening, analyzing and delivering actionable data on the competitive landscape to meet the unique requirements of the companies and individuals operating in the Apixaban market for the forecast period, 2018-2023. To enable firms to understand the Apixaban industry in various ways the report thoroughly assesses the share, size and growth rate of the business worldwide.

Get Your Free Sample Brochure of Apixaban market spread across [146 pages]@

Apixaban Market Set for Rapid Growth And Trend by 2025

Apixaban Market – Dynamics

Increasing prevalence of venous thromboembolism related conditions is expected to aid in growth of the apixaban market. For instance, according to International Society on Thrombosis and Haemostasis 2014 facts, revealed that around 10 million cases of venous thromboembolism occur annually across low, middle and high income countries. Moreover, increasing therapeutic indications for apixaban is expected to boost the apixaban market growth. For instance, in 2014, the U.S. Food and Drug Administration approved Eliquis for the treatment of deep vein thrombosis (DVT) prophylaxis and pulmonary embolism (PE) and also for the reduction in risk of recurrent PE and DVT following initial therapy. Furthermore, government and private organizations are significantly investing capital in healthcare research and development and this is also likely to propel growth of the Apixaban market. However, adverse effects of apixaban such as increased risk of thrombotic events after premature discontinuation and bleeding is expected to hamper adoption of this. This in turn is expected to adversely affect growth of the market. According to a study published in the Current Medical Research and Opinion 2017 stated about the bleeding risk associated with use of apixaban.